Journal
JOURNAL OF FUNGI
Volume 3, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/jof3010011
Keywords
Candida species; Candida glabrata; biofilm; candidiasis; resistance; antifungal; infection
Categories
Funding
- Programa Operacional, Fatores de competitividade COMPETE
- FCT-Fundacao para a Ciencia e a Tecnologia [FCT PTDC/SAU-MIC/119069/2010, RECl/EBB-EBI/0179/2012, PEst-OE/EQB/LA0023/2013]
- [SFRH/BD/93078/2013]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/93078/2013, PEst-OE/EQB/LA0023/2013, PTDC/SAU-MIC/119069/2010] Funding Source: FCT
Ask authors/readers for more resources
Infections caused by Candida species have been increasing in the last decades and can result in local or systemic infections, with high morbidity and mortality. After Candida albicans, Candida glabrata is one of the most prevalent pathogenic fungi in humans. In addition to the high antifungal drugs resistance and inability to form hyphae or secret hydrolases, C. glabrata retain many virulence factors that contribute to its extreme aggressiveness and result in a low therapeutic response and serious recurrent candidiasis, particularly biofilm formation ability. For their extraordinary organization, especially regarding the complex structure of the matrix, biofilms are very resistant to antifungal treatments. Thus, new approaches to the treatment of C. glabrata's biofilms are emerging. In this article, the knowledge available on C. glabrata's resistance will be highlighted, with a special focus on biofilms, as well as new therapeutic alternatives to control them.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available